Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F6KM
|
|||
| Former ID |
DCL001199
|
|||
| Drug Name |
ISIS-APOCIII
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Atherosclerosis [ICD-11: BD40] | Phase 1 | [1] | |
| Hyperlipemia [ICD-11: 5C80; ICD-10: E78.4, E78.5] | Phase 1 | [1] | ||
| Inflammation [ICD-11: 1A00-CA43.1] | Phase 1 | [1] | ||
| Metabolic syndrome x [ICD-11: 5C50-5D2Z] | Phase 1 | [1] | ||
| Company |
ISIS Pharm
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ApoC-III messenger RNA (APOC3 mRNA) | Target Info | . | [1] |
| KEGG Pathway | PPAR signaling pathway | |||
| Reactome | Chylomicron-mediated lipid transport | |||
| HDL-mediated lipid transport | ||||
| Retinoid metabolism and transport | ||||
| WikiPathways | Statin Pathway | |||
| PPAR Alpha Pathway | ||||
| Visual phototransduction | ||||
| Lipid digestion, mobilization, and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.